By integrating data across multiple studies, this analysis confirms that TissueCypher provides consistent, reproducible ...

BioTech Breakthrough’s Annual Awards Program Recognizes Innovation in the Global Life Sciences and Biotechnology Industry “We believe EsoGuard, the first and only commercially available diagnostic ...

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication ...

Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced new ...

ProPhase Labs announces BE-Smart's validation for esophageal disease diagnostics, achieving over 95% success in detecting critical biomarkers. ProPhase Labs Inc. announced the successful validation of ...

TissueCypher is Castle’s precision medicine risk-stratification test that predicts a patient’s individual risk of progression from Barrett’s esophagus (BE) to esophageal cancer FRIENDSWOOD, ...

FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has been selected as ...

Doctors may perform endoscopies to diagnose esophageal cancer. They may also order laboratory tests and other imaging tests, such as MRI and CT scans, to confirm the diagnosis and determine whether ...

Cancer of the esophagus claims more than 400,000 lives around the world each year. With no efficient, reliable method of screening for the disease, by the time symptoms become apparent, it's often too ...

Esophageal cancer is a difficult one to detect during its early stages, with most diagnosed only once the disease is well advanced, making it a difficult one to treat. A new type of breath test ...

Cancer of the esophagus claims more than 400,000 lives around the world each year. With no efficient, reliable method of screening for the disease, by the time symptoms become apparent, it's often too ...